Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;59(5):801-811.
doi: 10.1016/j.rcl.2021.05.008.

PET Imaging for Prostate Cancer

Bital Savir-Baruch  1 , Rudolf A Werner  2 , Steven P Rowe  3 , David M Schuster  4
Affiliations
Review

PET Imaging for Prostate Cancer

Bital Savir-Baruch et al. Radiol Clin North Am. 2021 Sep.

Abstract

The role of PET imaging with 11C-choline and 18F-fluciclovine in evaluating patients with prostate cancer (PCa) has become more important over the years and has been incorporated into the NCCN guidelines. A new generation of PET radiotracers targeting the prostate-specific membrane antigen (PSMA) is widely used outside the United States to evaluate patients with primary PCa and PCa recurrence. PET imaging influences treatment planning and demonstrates a significantly higher disease detection rate than conventional imaging such as computed tomography and MR imaging. Early data indicate that using PET radiotracers such as 18F-fluciclovine and PSMA improves patient outcomes. 68-Ga-PSMA-11 and 18F-DCFPyL-PET/CT were recently approved by the US Food & Drug Administration (FDA) for clinical use. Other PSMA radiotracers, including fluorinated variants, will likely gain FDA approval in the not-too-distant future.

Keywords: Biochemical recurrence; Fluciclovine; PET imaging; Prostate cancer; Prostate-specific membrane antigen; Theranostics.

PubMed Disclaimer

Conflict of interest statement

Disclosure B. Savir-Baruch: Grand sponsor and Consultant: Blue earth diagnostics, Lecturer: PET/NET and Blue earth diagnostics. R.A. Werner: Nothing to disclose. S.P. Rowe: Consultant, salary support, research funding from Progenics Pharmaceuticals, Inc.; Co-founder, consultant, equity in Precision Molecular, Inc.; Co-founder, consultant, equity in Plenary.ai, Inc. D.M. Schuster: Consultant: Syncona; AIM Specialty Health; Global Medical Solutions Taiwan; Progenics Pharmaceuticals, Inc. Participates through the Emory Office of Sponsored Projects in sponsored grants including those funded or partially funded by Blue Earth Diagnostics, Ltd; Nihon MediPhysics Co, Ltd.; Telix Pharmaceuticals (US) Inc.; Advanced Accelerator Applications; FUJIFILM Pharmaceuticals U.S.A., Inc; Amgen Inc.

MeSH terms